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Transforming growth factor- (TGF-) plays an important role in the development andmaintenance of embryonic dopaminergic (DA)
neurons in the midbrain. To study the function of TGF- signaling in the adult nigrostriatal system, we generated transgenic mice with
reduced TGF- signaling inmature neurons. Thesemice display age-relatedmotor deficits and degeneration of the nigrostriatal system.
Increasing TGF- signaling in the substantia nigra through adeno-associated virus expressing a constitutively active type I receptor
significantly reduces 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration and motor deficits.
These results suggest that TGF- signaling is critical for adult DA neuron survival and that modulating this signaling pathway has
therapeutic potential in Parkinson disease.
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Introduction
The progressive loss of dopaminergic (DA) neurons in the sub-
stantia nigra (SN) is a hallmark of Parkinson’s disease (PD;Dauer
and Przedborski, 2003). Transforming growth factor  (TGF-)
has multiple associations with the nigrostriatal system and with
PD (Roussa et al., 2009; Hegarty et al., 2014). TGF- is upregu-
lated in PD brains (Mogi et al., 1995), and genetic association
studies suggest that variation in the TGFB2 gene may influence
susceptibility to idiopathic PD (Goris et al., 2007). TGF- is es-
sential for the development and survival of embryonic DA neu-
rons (Roussa et al., 2009; Hegarty et al., 2014). TGF-2 or
TGF-3 knock-out mouse embryos display significantly reduced
numbers of DA neurons (Roussa et al., 2006; Zhang et al., 2007).
TGF- promotes the survival of embryonic DA neurons in cul-
ture and protects them against toxicity from the parkinsonism-
inducing toxinN-methylpyridinium ion (MPP; Krieglstein and
Unsicker, 1994; Poulsen et al., 1994; Krieglstein et al., 1995). Due
to the poor postnatal health and subsequent premature death of
TGF-2 or TGF-3 knock-out mice, it remained unclear whether
TGF- plays a role in adultDAneurons. TGF-2 haplodeficiency
(TGF-2/) mice are viable and have fewer DA neurons in the
SN at 6 weeks of age and display significantly reduced dopamine
concentration in the striatum in adulthood (6 months of age;
Andrews et al., 2006). The progressive loss of DAneurons and the
aggregation of -synuclein are observed in Smad3 (a key compo-
nent of the TGF- signaling pathway) null mice at 2–3months of
age and in Smad3 haplodeficiency mice at 19–20 months of age
(Tapia-Gonza´lez et al., 2011). These results suggest that defi-
ciency in TGF- signalingmay increase the risk of developing PD
and that modulating this pathway may have therapeutic effects.
However, several studies failed to show protective effects of
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Significance Statement
We show that reducing Transforming growth factor- (TGF-) signaling promotes Parkinson disease-related pathologies and
motor deficits, and increasing TGF- signaling reduces neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a
parkinsonism-inducing agent. Our results provide a rationale to pursue a means of increasing TGF- signaling as a potential
therapy for Parkinson’s disease.
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TGF- in animal models of PD. Continuous administration of
TGF-3 over substantia nigra failed to prevent 6-hydroxydopamine-
induced neuronal cell death in rat (Sauer et al., 1995). In mice,
overexpression of TGF-1 in the striatum by adenovirus exacer-
bates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced
loss of DA neurons and enhances dopamine depletion in the stria-
tum (Sa´nchez-Capelo et al., 2003). These findings are in striking
contrast to the in vitro observation that TGF- protects embry-
onic DA neurons against MPP-induced degeneration (Kriegl-
stein and Unsicker, 1994; Poulsen et al., 1994; Krieglstein et al.,
1995). The cause of these contradictory results is not known and
could be due to the fact that in vivo delivery of the TGF- ligands
may initiate TGF- signaling in many cell types in vivo, since
essentially all cell types in the brain express TGF- receptors.
Given the highly cell type-specific and context-dependent nature
of TGF- signaling, it is important to study the role of TGF-
signaling in disease progression in a cell type-specific manner to
determine whether the TGF- signaling pathway may serve as a
potential therapeutic target for promoting the survival of DA
neurons. In this study, we used transgenic mice and viral-mediated
gene transfer to drive the expression of mutant TGF- receptors to
achieve cell type-specific manipulation of TGF- signaling in neu-
rons.We show that reducing TGF- signaling inmature neurons in
transgenic mice causes age-related motor deficits and degeneration
of the nigrostriatal system. Importantly, increasing TGF- signaling
in the substantia nigra reduces MPTP-induced dopaminergic neu-
rodegeneration andmotor deficits.
Materials andMethods
Mice
Transgenic mice expressing tTA (tetracycline-controlled transactivator)
under control of the CaMKII promoter (CaMKII-tTA mice; Fan et al.,
2001) and transgenic mice expressing a truncated, kinase-defective
TGF- type II receptor (TBRIIk) under the control of tetO regulatory
sequences (tetO-TBRIIk mice; Tesseur et al., 2006) were crossed to
generate CaMKII-tTA/TBRIIk mice. Littermate CaMKII-tTA/
TBRIIk mice were used as controls. TBRIIk functions as a potent
inhibitor of TGF- signaling in neurons and is tagged with a flag epitope
(Tesseur et al., 2006). Male, wild-type C57BL/6 mice were purchased
from The Jackson Laboratory. All mice were kept under a 12 h light/dark
cycle with ad libitum access to food and water. All animal care and pro-
cedures complied with the Animal Welfare Act and were performed in
accordance with institutional guidelines and approved by the VA Palo
Alto institutional animal care and use committee.
Behavior analysis
Rotarod test. Mice were tested on a rotarod apparatus to assess coordina-
tion and balance, according to published procedures (Luo et al., 2014).
The mice were placed on the rotating rotarod for 1 min at 3 rpm, after
which the speedwas accelerated to 40 rpmover 5min, and the latency (in
seconds) to fall was recorded. Eachmouse underwent three test sessions,
and the best time was chosen for analysis.
Pole test. For the pole test, the mouse was placed head upward on the
top of a vertical wooden pole (diameter, 1 cm; height, 50 cm) with a
rough surface (Ogawa et al., 1985). Each mouse was trained to habituate
to the pole for two trials and then allowed to descend five times on a single
session. The time in which themouse reached the floor with all four paws
was recorded.
Morris water maze. Spatial learning and memory was assessed by the
Morris water maze (MWM; Chin et al., 2005; Roberson et al., 2007). The
water maze pool (diameter, 152 cm) contained opaque water (22–23°C)
with a platform (15 15 cm) submerged 1.5 cm below the surface. Mice
were trained to locate a cued (days 1–3) or hidden (days 4–8) platform.
A black and white-striped mast (15 cm height) was mounted on the
platform for cued training sessions andwas removed for hidden platform
sessions. Each day themice were tested for two sessions (3.5 h apart), and
each session consisted of two (cued training) or three (hidden platform)
60 s trials with a 15 min intertrial interval. The platform location was
changed for each cued training session but remained constant in the
hidden platform sessions. A 60 s probe trial (with platform removed) was
performed at 24 h after completion of the hidden platform sessions. The
entry point for the probe trials was in the quadrant opposite to the target
quadrant. Performance was analyzed using the EthoVision Automated
Tracking System (Noldus Information Technology).
Gait analysis. Forelimb and hindlimb paws were painted with red and
blue nontoxic paint (Brooks and Dunnett, 2009). Mice were placed on a
brightly lit platform (15  15 cm) from which they could escape into a
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Figure 1. Expression of the transgene in CaMKII-tTA/TBRIIk mice. CaMKII-tTA/
TBRIIk mice were generated by crossing CaMkII-tTA mice with tet-O-TBRIIk mice
expressing a kinase-deficient TGF- type II receptor. CaMKII-tTA/TRIIk and CaMKII-
tTA/TBRIIk (as control) mice were killed at 2 months of age and their brains were sec-
tioned sagittally. The transgeneexpressionwas visualizedby immunostainingwithanantibody
against a flag epitope (present in TBRIIk).A, A representative image of flag immunoreactivity
in different brain regions. Note the strong flag immunoreactivity in the striatum. B, Higher-
magnification images showing flag immunoreactivity in thehippocampus, cortex, and striatum
in the CaMKII-tTA/TBRIIk mice (left panels), compared with CaMKII-tTA/TBRIIk
mice (right panels). Scale bar, 50m. C, Tissue lysates from different brain regions were sub-
jected to Western blot analysis using anti-flag and-actin antibodies.
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dim hut along a 100-cm-long and 7-cm-wide runway lined with white
paper. Each mouse was tested in three trials per day with an intertrial
interval of 5 min over 3 consecutive days. Six steps from the middle
portion of each run were analyzed for stride length, hind-base width (the
distance between the right and left hindlimb strides), front-base width
(the distance between the right and left frontlimb strides), and paw angle
(paws central axis relative to its walking direction). Mean values were
used for statistical analysis.
Tissue processing
Mice were perfused transcardially with saline, and one hemi-brain was
fixed for 24 h in 4% paraformaldehyde and equilibrated in 30% sucrose
for histological analysis, as previously described (Luo et al., 2007). The
other hemi-brain was snap frozen and stored at80°C for biochemical
analysis. For stereological analysis of DA neurons in the substantia nigra,
the whole brain was fixed and sectioned.
Immunohistochemistry
Immunohistochemistry was performed on free-floating sections follow-
ing standard procedures (Luo et al., 2006, 2007). The following primary
antibodies were used: flag (1:1000; catalog #F1804, Sigma-Aldrich; RRID:
AB_262044); CD68 (1:50; catalog #MCA1957, Bio-Rad; RRID: AB_322219;
Luo et al., 2013); c-Fos (1:1000; catalog #PC38,Millipore; RRID:AB_2106755);
calbindin (1:10,000; catalog #CB 38, Swant; RRID: AB_10000340); NeuN (1:
1000;catalog#MAB377,Millipore;RRID:AB_2298772);andp-Smad2(1:1000;
catalog #AB3849,Millipore; RRID: AB_11213091). After overnight incuba-
tion, primary antibody staining was revealed using biotinylated
secondary antibodies and the ABC Kit (Vector Laboratories) with di-
aminobenzidine (DAB; Sigma-Aldrich). Photographs were acquired us-
ing a BX51 Microscope (Olympus) and a SPOT Flex shifting pixel CCD
camera with SPOT Advanced software (SPOT Imaging Solutions). The
number of Purkinje cells was evaluated on calbindin-immunostained
sections, according to a previously established method (Buffo et al.,
1997). Briefly, the number of Purkinje cells in five serial sections were
counted for each mouse. The length of the Purkinje cell layer was mea-
sured using MetaMorph Microscopy Automation and Image Analysis
Software (Molecular Devices; RRID: SCR_002368), and the density was
determined by dividing the number of Purkinje cells by this length. The
number of NeuN neurons in the spinal cord was estimated accord-
ing to the study by Ross et al. (2010), using the cell count function of
MetaMorph and validated by manual counts.
Cresyl Violet staining
Brain sectionsweremounted on Superfrost Plus slides (Fisher Scientific),
air dried, rehydrated, and stained with 0.02% Cresyl Violet (Sigma-
Sigma) in acetate buffer, pH3.2, thenwere dehydrated through a series of
alcohols, cleared in xylene, and coverslipped. The number of neurons in
the CA1 pyramidal cell layers was quantified with MetaMorph Imaging
software (Luo et al., 2006).
Real-time quantitative PCR
The striata were dissected from saline-perfused mice, flash frozen on dry
ice, and stored at80°C. RNA was extracted using an RNeasy Mini Kit
(Qiagen) according to the manufacturer instructions. A total of 1000 ng
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Figure 2. Mice with reduced TGF- signaling in neurons display learning, memory, and motor deficits. A–C, CaMKII-tTA/TBRIIk and CaMKII-tTA/TBRIIk (as control) mice were
tested for spatial learning andmemory function using MWM. A, The average escape latency of each session in the visible platform (1–6 sessions) and hidden platform (7–16 sessions) parts of the
MWM test. Themice underwent a probe test 24 h later. B, C, Travel routes (B) and the time spent in the target and opposite quadrants (C) were analyzed using the EthoVision Automated Tracking
System.D–F, Footprint analysis was performed at 18months of age. Representative paw prints of CaMKII-tTA/TBRIIkmice and CaMKII-tTA/TBRIIkmice (as a control) are shown inD.
E,F, Quantification of hindlimb (blue prints,E) and forelimb (redprints,F ) stride length.C,E,F, Bars represent themean SEMandwere analyzedbyANOVA (C) or unpaired t test (E,F ). *p0.05;
**p 0.01. n 10–12 mice/group.
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of RNA was treated with DNase I (Invitrogen) and then converted to
cDNA using the SuperScript III First Strand Synthesis System
(Invitrogen). cDNA was diluted 1:10 in water. Real-time quantitative
PCR (qPCR) was performed using SYBRGreen IMasterMix (Roche) on
a LightCycler 480 (Roche). The following primers were used: for induc-
ible nitric oxide synthase (iNOS) 2: forward primer, GTTCTCAGCCCAA
CAATACAAGA; reverse primer, GTGGACGGGTCGATGTCAC; for
tumor necrosis factor- (TNF-): forward primer, TGGAACTGGCAGA
AGAG; reverse primer, CCATAGAACTGATGAGAGG; formonocyte che-
moattractant protein 1 (MCP-1): forward primer, TTA AAA ACC TGG
ATCGGA ACC AA; reverse primer, GCA TTAGCT TCAGAT TTA CGG
GT; and for actin: forward primer, GGC TGT ATT CCC CTC CAT CG;
reverse primer, CCAGTTGGTAACAATGCCATGT.
Melting curves were used to confirm the purity of the amplified prod-
uct. Cycle threshold (Ct) values were normalized to actin. Ct values
were used to yield the fold change over control
in each experiment (Villeda et al., 2014; Kirby
et al., 2015).
Western blot analysis
Brain regions were dissected after perfusion of
the animal, snap frozen, and lysed in RIPA lysis
buffer (500 mM Tris, pH 7.4, 150 mM NaCl,
0.5% Na deoxycholate, 1% NP40, 0.1% SDS,
andcompleteprotease inhibitors;Roche;Villeda et
al., 2014; Kirby et al., 2015). The total protein
concentration was quantified using a bicin-
choninic acid kit (Pierce). Tissue lysates were
mixed with 4 NuPage LDS loading buffer
(Invitrogen), loaded on a 4–12% SDS poly-
acrylamide gradient gel (Invitrogen) and sub-
sequently transferred onto a nitrocellulose
membrane. The blots were blocked in 5%milk
in Tris-buffered saline with Tween and incu-
bated with anti-actin (1:5000; catalog #A5060,
Sigma-Aldrich; RRID:AB_476738) and anti-flag
(1:1000; catalog #F1804, Sigma-Aldrich; RRID:
AB_262044). Flag signals were detected by
horseradish peroxidase-conjugated secondary
antibodies and an ECL kit (GE Healthcare/
Pharmacia Biotech). For c-Fos analysis, the
striata were dissected from the brain sections
under a microscope, and proteins were ex-
tracted using the Qproteome FFPE Tissue Kit
(Qiagen). The proteins were visualized and
quantified on a LI-COR Odyssey IR Imaging
System (Odyssey CLx; RRID:SCR_014579).
Adeno-associated virus preparation
Adeno-associated virus (AAV) expressing
ALK5CA-T2A-eGFP under a cytomegalovirus
(CMV) promoter (AAV-ALK5CA) was gener-
ated at the Stanford Neuroscience Gene Vector
and Virus Core. ALK5CA, a constitutively ac-
tive mutant of ALK5 containing a T204D sub-
stitution (Wieser et al., 1995), was isolated from
pCMV5-rALK5CA-HA (obtained from Joan
Massague, Memorial Sloan Kettering Cancer
Center, New York, NY). AAV expressing T2A-
eGFP (AAV-GFP) was generated as a control.
AAVs were generated with AAV-DJ capsids
(Grimm et al., 2008) for high-efficiency in vivo
neuronal infection (Xu et al., 2012; Villeda et al.,
2014).
Stereotaxic injection of AAV
Male, wild-type C57BL/6 mice (8 weeks old;
The Jackson Laboratory) were used. Stereo-
taxic injections were performed under isoflu-
rane anesthesia with a 5 l Hamilton syringe.
After each mouse was placed in a stereotaxic
frame, 1l of the vector suspended in PBS (5 108 infectiousU/ml) was
injected into the substantia nigra over 5 min. The following coordinates
were used for substantia nigra (2.9 mm posterior to the bregma, 1.3 mm
lateral to the midsagittal suture, and 4.2 mm ventral to the skull; Bensa-
doun et al., 2000).
MPTP injury
Two weeks after AAV stereotaxic injection, MPTP (M103, Sigma-
Aldrich) was injected intraperitoneally based on a published protocol
(8 mg/kg in saline, 4 times/d, 2 h apart, for 2 d; Martens et al., 2012).
Seven days after the last MPTP injection, mice were perfused and brains
were collected for immunohistochemistry and stereological estimation
of dopaminergic neurons.
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Figure 3. Micewith reduced TGF- signaling in neurons display degeneration of the nigrostriatal system. CaMKII-tTA/TBRIIk
micewere generatedby crossing CaMkII-tTAmicewith tet-O-TBRIIkmice expressing a kinase-deficient TGF- type II receptor. CaMKII-
tTA/TBRIIkmicewereusedas controls.A,B, Brain sections fromthesemicewere immunostainedwithanantibodyagainst THand
weresubjectedtostereologicalanalysisofTHDAneurons insubstantianigraparscompacta(A)andTHnerveterminals inthestriatum
(B). C, E, Brain sections were immunostained with an antibody against calbindin, and calbindin immunoreactivity was measured in the
striatum (C) and hippocampal CA1 (E). D, Brain sections were stained with 0.02% Cresyl Violet. Scale bar, 50m. Bars represent the
mean SEMandwere analyzed by unpaired t test. *p 0.05; **p 0.01.n 10–12mice/group.
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Stereological estimation of dopaminergic
neurons in the substantia nigra
The number of dopaminergic neurons in the
substantial nigra was estimated stereologically
(Zhang et al., 2007; Martens et al., 2012). Briefly,
whole-brain sections containing substantia nigra
were stained with an antibody against tyrosine
hydroxylase (TH; 1:200; catalog #AB152, Milli-
pore; RRID: AB_390204) with the ABC kit and
DAB. Stereological counting of bregma 2.8 to
4.04mm(six serial sections)was used to quan-
tify the number of TH neurons in the substan-
tia nigra, according to previously described
procedures (Zhang et al., 2007; Martens et al.,
2012).
Data and statistical analysis
Data are presented as the mean  SEM. Data
were analyzed using a two-tailed Student’s t
test for comparing two groups or ANOVA for
comparing multiple groups. A Bonferroni’s or
Turkey’s post hoc test was used to compare
pairs of groups following ANOVA. Statistical
analysis was performed with Prism software
(GraphPad; RRID:SCR_002798). A p value of
0.05 was considered to be statistically
significant.
Results
Mice with reduced TGF- signaling in
mature neurons display age-related
memory andmotor deficits
Wehave previously shown that reducing neuronal TGF- signal-
ing in mice resulted in age-dependent neurodegeneration and
promoted amyloid- accumulation and dendritic loss in amouse
model of Alzheimer’s disease (Tesseur et al., 2006). To further
study the function of TGF- signaling specifically in neurons, we
generated double transgenic CaMKII-tTA/TBRIIk mice by
crossing CaMKII-tTAmice (Mayford et al., 1996), with tet-O-
TBRIIkmice expressing kinase-deficient TGF- type II recep-
tor (TBRIIk; Tesseur et al., 2006). TBRIIk functions as a
potent inhibitor of TGF- signaling and has been used in other
transgenic mice to specifically inhibit signaling in pancreatic or
skin cells (Bo¨ttinger et al., 1997; Wang et al., 1997). Immuno-
staining with a flag antibody showed expression of the flag
epitope (presented in TBRIIk) in the hippocampus, cortex, and
striatum (Fig. 1A), which is consistent with previous reports
about the CaMKII-tTAmice (Mayford et al., 1996; Kholodilov
et al., 2004). Weak, scattered flag immunoreactivity was also ob-
served in the brainstem and cerebellum (10% of cells). No flag
immunoreactivity was observed in the substantia nigra. Among
the forebrain regions, the striatum showed the most intense flag
immunoreactivity (Fig. 1B). In addition,Western blot analysis of
the flag epitope confirmed the expression of flag and TBRIIk in
the above brain regions (Fig. 1C).
TheCaMKII-tTA/TBRIIkmice (the TBRIIkwas left on
throughout the experiment) displayed moderate learning and
memory deficits, as assessed by the MWM, and severe motor
deficits, as assessed by gait analysis (Fig. 2), at 18months of age. In
the Morris water maze test, the CaMKII-tTA/TBRIIk mice
showed significantly longer escape latencies in the hidden plat-
form tests (Fig. 2A) and spent less time in target quadrant in the
probe trial (Fig. 2B,C). Footprint analysis showed both hindlimb
and forelimb stride length was significantly reduced compared
with CaMKII-tTA/TBRIIk control mice (Fig. 2D–F). The
distance between the forelimbs during stance was also signifi-
cantly reduced in the CaMKII-tTA/TBRIIk mice, whereas
there was a tendency toward smaller hindlimb stance, but this
was not significantly different (data not shown). In addition,
	38% of the CaMKII-tTA/TBRIIk mice (n  7) displayed a
series of severe symptoms, including tremor of the head in the rest-
ing position, impairments in righting reflex, a hunched back with
kyphosis, a prolapsed rectum, and loss of hair and excoriated skin.
They were not able to complete the rotarod and pole tests and
showedmore profound gait impairments in footprint analysis.
CaMKII-tTA/TBRIIkmice display degeneration of the
nigrostriatal system
To determine whether the motor deficits in the CaMKII-tTA/
TBRIIkmice are related to the disruption of the nigrostriatal
system, brain sections were immunostained for TH to label DA
neurons and subjected to stereological quantification, according
to published methods (Zhang et al., 2007; Martens et al., 2012).
The CaMKII-tTA/TBRIIk mice showed a 20% decrease in
the number of THDAneurons in the SNpars compacta (SNpc)
and a 40% reduction in TH fiber density in the striatum, com-
pared with CaMKII-tTA/TBRIIk mice (Fig. 3A,B). To de-
termine whether there is cell loss in other brain regions, we
performed Cresyl Violet staining and immunostaining with
NeuN and calbindin. Compared with the CaMKII-tTA/
TBRIIk mice, the CaMKII-tTA/TBRIIk mice did not
show obvious abnormal brain morphology or cell loss in
the hippocampus (Fig. 3D), cerebellum, or spinal cord. The
mean number of calbindin Purkinje cells was 52.92  13.68
and 50.95  3.89/mm in the CaMKII-tTA/TBRIIk and
CaMKII-tTA/TBRIIkmice, respectively (p 0.892, by two-
tailed t test). The mean number of NeuN neuron cells in the
spinal cord was 210.8 19.29 and 167.9 17.72/ventral horn in
the CaMKII-tTA/TBRIIk and CaMKII-tTA/TBRIIk
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Figure4. MicewithreducedTGF-signalingdisplay increasedexpressionofc-Fos.A,B,BrainsectionsfromCaMKII-tTA/TBRIIk
orCaMKII-tTA/TBRIIkmicewere immunostainedwithanantibodyagainst c-Fos,andc-Fos cellswereanalyzed in thehippocam-
pus (dentate gyrus; A) and striatum (B). C, RepresentativeWestern blot analysis of striatal lysates probed with anti-c-Fos and anti-actin
antibodies. c-Fos expression was quantified and normalized to actin with a LI-COR Odyssey IR Imaging System. Scale bar, 50m. Bars
represent themean SEMandwere analyzed by unpaired t test. *p 0.05.n 10–12mice/group.
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mice, respectively (p 0.129, by two-tailed t test). However, the
calbindin immunoreactivity was significantly reduced in the
striatum (Fig. 3C) and hippocampus (Fig. 3E) of the CaMKII-
tTA/TBRIIk mice. These results suggested that reduced
TGF- signaling in the forebrain led to damage of DA nerve
terminals in the striatum and loss of DA neurons in the SN and
that the motor deficits observed in CaMKII-tTA/TBRIIk
mice may be related to dysfunction of the nigrostriatal system.
Expression of the immediate early gene c-fos increases in re-
sponse to depolarization and is therefore an in vivomarker for neu-
ronal activation (Sagar et al., 1988). c-fos and Fos protein have been
widely used to investigate basal ganglia responses to changes in do-
paminergic neurotransmission.DecreasedDA input to the striatum
induces increasedFosexpression in the striatalneurons (ColeandDi
Figlia, 1994). The activity of c-fos has also been used to assess the
response of striatal neurons to levodopa following the destructionof
substantia nigra (Robertson et al., 1989). To determine whether re-
duced TGF- signaling affected the expression of c-Fos, we per-
formed immunostaining with an antibody against c-Fos. The
CaMKII-tTA/TBRIIk mice showed significant increase of
c-Fos expression in the striatum and hippocampus (Fig. 4A,B). In
agreementwith the immunohistochemistrydata,Westernblot anal-
ysis of striatal lysates revealed significantly increased expression of
c-Fos in the CaMKII-tTA/TBRIIkmice (Fig. 4C).
Increasing TGF- signaling in the substantia nigra through
AAV-Alk5CA
Since reducing TGF- signaling in CaMKII-tTA/TBRIIk
mice led to the dysfunction of the nigrostriatal system, we hy-
pothesized that increasing TGF- signaling would rescue DA
neurons and restore functional deficits. Wemade use of a consti-
tutively active form of TGF- type I receptor Alk5 (Alk5CA) and
generatedAAVthat encodesGFP/ALK5CA (termedAAV-Alk5CA; Fig.
5A) or encodes only GFP (AAV-GFP) as a control. Alk5CA, a
constitutively active mutant of ALK5 containing a T204D substi-
tution, activates TGF- signaling in a ligand-independent man-
ner (Wieser et al., 1995) and has been used in transgenic mice to
activate TGF- signaling in a cell type-specificmanner (Bartholin
et al., 2008). AAVs were generated with AAV-DJ capsids (Grimm
et al., 2008) for high-efficiency in vivo neuronal infection (Xu et
al., 2012; Villeda et al., 2014). We injected these viruses into the
substantia nigra of wild-type mice by stereotaxic surgery. Two
weeks after injection, themice were killed to analyze GFP expres-
sion (Fig. 5B,D) and TGF- signaling (Fig. 5C). The AAV-
Alk5CA side showed increased phospho-Smad 2 immunoreactivity,
suggesting the activation of TGF- signaling. The colocalization
of GFP (green) and TH (red) immunoreactivity demonstrated
the expression of the reporterGFP (andAlk5CA) in dopaminergic
neurons (Fig. 5D). The majority of infected cells (GFP) are
neurons (81 11%; n 4 mice).
Delivery of AAV-Alk5CA significantly reduces MPTP-induced
dopaminergic neurodegeneration andmotor deficits
To test our hypothesis above, we investigated whether local de-
livery of AAV-Alk5CA might exert protection against the degen-
eration of DA neurons induced by neurotoxin MPTP, which is
commonly used in experimental parkinsonism (Meredith and
Rademacher, 2011). We first injected AAV-Alk5CA stereotaxi-
cally into the right substantia nigra and AAV-GFP into the left
substantia nigra of each wild-type mouse. Two weeks later, mice
receivedMPTP to induce dopaminergic degeneration, according
to a published dosing regimen (Martens et al., 2012). Five days
after the last MPTP injection, mice were killed and analyzed for
dopaminergic neurodegeneration and microgliosis (Fig. 6). The
right substantia nigra (received AAV-Alk5CA) showed signifi-
cantly more TH dopaminergic neurons than the left side (re-
ceived AAV-GFP as a control; Fig. 6A). Consistent with this
observation, the right striatum showed significantly higher inten-
sity of TH immunoreactivity (Fig. 6B). The reduced neurodegen-
eration in the AAV-Alk5CA side was mirrored by microglial
response. Reactivemicrogliameasured byCD68 immunoreactiv-
itywasmarkedly reduced in theAAV-Alk5CA side comparedwith
the AAV-GFP control side (Fig. 6C). In addition, the expression
of proinflammatory mediators TNF-, iNOS, and MCP-1 in the
striata were all significantly reduced in the AAV-Alk5CA side
compared with the AAV-GFP control side (Fig. 6D–F).
To further study the effects of AAV-Alk5CA, we injected AAV-
Alk5CA stereotaxically into both sides of the substantia nigra of
A
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D
Figure 5. Generating AAV-encoding Alk5 CA to activate TGF- signaling in dopaminergic neurons. A, Schematic structure of AAV-encoding Alk5 CA and GFP (termed AAV-Alk5 CA). In addition,
AAV-GFP was generated as a control (data not shown). B–D, AAV-Alk5 CA or AAV-GFPwas injected into the substantia nigra of wild-typemice, and 2 weeks later themice were killed and analyzed
for GFP expression (B, D) and TGF- signaling (C). The substantia nigra is outlined in B and C, with insets in C showing higher magnification. Dopaminergic neurons were immunolabeled with an
antibody against TH (red), and the reporter gene (GFP, green) and Alk5 CA expressing cells appear yellow after superimposition (D). Scale bars: B, C, 50m; D, 20m.
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wild-type C57BL/6 mice (male, 2 months
of age). AAV-GFP as a control was in-
jected in another set of animals. Two
weeks later, half of the mice from both
groups was injected with MPTP (Martens
et al., 2012) and the other half was injected
with PBS. We used a battery of behavioral
tests to assess motor function 5 d after the
last MPTP injection (Fig. 7). Home-cage
behavior monitored with the Smart-
Homecage platform (Luo et al., 2014) re-
vealed no difference between the mice
receiving AAV-GFP and those receiving
AAV-Alk5CA after being injected with
PBS (Fig. 7A–C). MPTP caused signifi-
cant impairments in locomotor behavior
in mice receiving AAV-GFP, but AAV-
Alk5CA mice showed significantly im-
proved locomotor behavior, as shown by
moving distance (Fig. 7A), activity counts
(Fig. 7B), and active time (Fig. 7C). In ad-
dition, the animals receivingAAV-Alk5CA
performed significantly better in the pole
andwire hang tests (Fig. 7D,E) than those
receiving AAV-GFP after MPTP adminis-
tration. Thus, the delivery of AAV-Alk5CA
significantly reduced motor deficits asso-
ciated with MPTP injury. Postmortem
stereology revealed that themice receiving
AAV-GFP and those receiving AAV-
Alk5CA had similar estimated numbers of
THDA neurons in the SNpc after being
injected with PBS. MPTP caused a signif-
icant loss of DA neurons in the SNpc, but
the number of TH DA neurons in the
SNpc was significantly higher in the mice
receiving AAV-Alk5CA than in those re-
ceiving AAV-GFP (Fig. 7F). Similarly, a
higher intensity of TH immunoreactivity
in the striatum (Fig. 7G) and reduced
CD68 immunoreactivity in the SNpc (Fig.
7H) were observed in the mice receiving
AAV-Alk5CA compared with those re-
ceiving AAV-GFP after MPTP injection.
In summary, stereotaxically delivering AAV-
Alk5CA into the substantia nigra provides
potent neuroprotective effects against
MPTP.
Discussion
Our results demonstrate that deficiency in neuronal TGF- sig-
naling promotes a parkinsonian phenotype and that TGF- sig-
naling activation through AAV-Alk5CA protects mice from
MPTP neurotoxicity. They highlight the essential role of TGF-
signaling in adult DA neurons and support TGF- signaling as a
potential therapeutic target for PD. Our results are in line with
studies showing that mice with reduced TGF- signaling
(through TGF-2 or Smad3 haplodeficiency) show fewer DA
neurons in the substantia nigra in adulthood (Andrews et al.,
2006; Tapia-Gonza´lez et al., 2011). While TGF- signaling was
reduced globally in those studies, our genetic study using
CaMKII-tTA mice allowed us to specifically reduce TGF- sig-
naling postnatally in neurons, thus linking TGF- signaling in
terminally differentiated, mature neurons to PD. By using a
double-transgenic approach, we achieved regionally selective ex-
pression of TBRIIk in projection targets of the mesencephalic
dopaminergic system. The expression of TBRIIk in the striatum
(but not in the substantia nigra) and the loss ofDAneurons in the
substantia nigra in ourmodel suggest that reduced TGF- signal-
ing in the striatum contributes to the loss of DA neurons in the
substantia nigra. This observation appears to support the “dying-
back” hypothesis (Dauer and Przedborski, 2003), that is, the de-
generation of striatal terminals caused by reduced TGF-
signaling may lead to the loss of neuronal cell bodies in the sub-
stantia nigra. These results also suggest that the DA neurons may
be particularly sensitive to a reduction of TGF- signaling. It has
A
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Figure 6. Delivery of AAV encoding Alk5 CA significantly reduces MPTP-induced dopaminergic neurodegeneration and micro-
gliosis. AAV-Alk5 CAwas stereotaxically injected into the right substantia nigra, and AAV-GFPwas injected as a control into the left
substantia nigra of the samewild-type C57BL/6mice (male, 2months of age). Twoweeks later,micewere injectedwithMPTP and
were killed 5 d later.A–C, MPTP-induced dopaminergic neurodegenerationwas assessed by TH immunostaining in the substantia
nigra pars compacta (A, stereological estimation of THneurons) and striatum (B, intensity of TH immunoreactivity), and reactive
microglia were assessed by CD68 immunostaining (C). D–F, mRNA was isolated from the striata, and the expression of TNF-,
iNOS, and MCP-1 was analyzed by qPCR. Scale bars: A–C, 200m. Bars indicate the mean SEM. *p 0.05; **p 0.01, by
paired t test. n 7 mice/group.
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been shown that TGF- signaling is reduced in the aged brain
(Tichauer et al., 2014). Therefore, our findings may have impli-
cations for the pathogenesis of sporadic Parkinson’s disease. In
addition, our findings support the notion that the motor deficits
observed in the CaMKII-tTA/TBRIIk mice are likely due to
the degeneration of nigrostriatal system. However, we are not
able to exclude the contribution from other brain areas. It would
be of particular interest to investigate in the future whether the
injection of AAV-Alk5CA into the striatum or substantia nigra
will rescue the motor deficits and nigrostriatal degeneration in
the CaMKII-tTA/TBRIIkmice.
In contrast to previous attempts, which failed to protect DA
neurons through the administration of TGF-3 or the overex-
pression of TGF-1 (Sauer et al., 1995; Sa´nchez-Capelo et al.,
2003), our approach through AAV-Alk5CA significantly reduced
MPTP-induced DA neurodegeneration, neuroinflammation, and
motor deficits. While every cell type in the brain may respond to
TGF-1 or TGF-3 in those earlier studies (Sauer et al., 1995;
Sa´nchez-Capelo et al., 2003), our viral approach allowed us to
increase TGF- signalingmore specifically in neurons. Given the
cell type-specific nature of TGF- signaling, we believe that cell
type-specific manipulation of TGF- signaling contributes, at
least partially, to the potent protective effects we observed in our
studies. During the past 30 years, AAV has been widely explored
as a gene therapy tool (Kotterman and Schaffer, 2014; Samulski
and Muzyczka, 2014). AAV-mediated delivery of the TGF- su-
perfamily proteins, such as glial cell line-derived neurotrophic
factor, neurturin, and growth/differentiation factor 5, has been
examined for the ability to protect and/or restore degenerating
dopaminergic neurons in animal models and in clinical trials
(Bartus et al., 2014; Kelly et al., 2015). While these approaches
involve delivering the ligands, our approach takes advantage of a
constitutively active form of the receptor, thus offering an alter-
native and effective approach.
Altogether, our results support a critical role of TGF- signal-
ing in mature neurons. They suggest that TGF- signaling may
present a therapeutic target for PD and provide a strong proof of
concept for testing AAV-Alk5CA and related approaches in addi-
tional preclinical studies for PD toward possible use in patients.
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